Improvement of chronic HCV infection‐related depression, anxiety, and neurocognitive performance in persons achieving SVR‐12: A real‐world cohort study

Kaur, Harmanpreet; Dhiman, Radha K.; Kulkarni, Anand V.; Premkumar, Madhumita; Singh, Virendra; Duseja, Ajay; Grover, Sandeep; Grover, Gagandeep Singh; Roy, Akash; Verma, Nipun; De, Arka; Taneja, Sunil; Mehtani, Rohit; Mishra, Saurabh; Kaur, Harpreet

doi:10.1111/jvh.13668

Cited by 7 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed a significant improvement in the anxiety/depression domain following HCV clearance in our study. Previous research also indicated that HCV eradication led to a decrease in anxiety prevalence from 30.4 to 19.1% and depression from 35.2–18.2% [ 37 , 38 ]. Furthermore, patients with severe mental illness and hepatitis C virus infection can benefit from DAAs treatment [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

Sustained virologic response improved the long-term health-related quality of life in patients with chronic hepatitis C: a prospective national study in China

Huang,

Shang,

Chen

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

Background To investigate the trends in health-related quality of life (HRQoL) among hepatitis C virus (HCV) patients and to assess the longitudinal impact of antiviral therapy on their well-being. Methods In this prospective multicenter observational study in adults with HCV infection, sociodemographic, clinical characteristics and EQ-5D questionnaires were collected. Generalized estimating equation (GEE) models were used to assess the associations between these variables and changes in HRQoL over time. Results 456 patients were included, with a median age of 46.5 (36.5–57.0) years, of which 262 (57.5%) were males and 44 (9.6%) had cirrhosis. 335 patients (73.5%) receiving antiviral therapy and 61.8% achieved sustained virologic response (SVR). The baseline EQ-5D utility and EQ-VAS were 0.916 ± 0.208 and 80.6 ± 13.0. In multivariable analysis of GEE estimation, achieving SVR24 was positively associated with EQ-5D utility (p = 0.000) and EQ-VAS (p = 0.000) over time. Age and income were shown to be significant predictors of EQ-5D utility, while gender, age and genotype were associated with EQ-VAS over time. Conclusions SVR improved long-term HRQoL in HCV patients in the first few years following viral clearance. Certain sociodemographic factors, such as gender, age, income as well as genotype, significantly influenced long-term changes in patients’ quality of life. Trial registration NCT01594554. Registration date: 09/05/2012.

show abstract

Section: Discussionmentioning

confidence: 99%

Sustained virologic response improved the long-term health-related quality of life in patients with chronic hepatitis C: a prospective national study in China

Huang,

Shang,

Chen

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…There was no significant difference between the Tx-naïve DAA group and IFN group in the risk of other NPDs which included psychotic disorders and cognitive disorders (HR = 1.11, 95% CI: 0.45–2.73, p = 0.819). However, improving cognitive and neuropsychological outcomes among the CHC patients achieving SVR has been shown in several studies conducted using self-control scale measurement in a short follow-up time ( Barbosa et al, 2017 ; Evon et al, 2019 ; Hassaan et al, 2019 ; Kesen et al, 2019 ; Fabrazzo et al, 2020 ; Vaghi et al, 2020 ; Ibáñez-Samaniego et al, 2022 ; Kaur et al, 2022 ; Mahran et al, 2022 ). The previous studies evaluated differences in mean scores of symptom clusters between pre-treatment and post-treatment assessment, at 12 weeks to 6 months after therapy completion.…”

Section: Discussionmentioning

confidence: 99%

Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study

Fang

Lin

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Data on the neuropsychological outcomes after receiving direct-acting antivirals (DAAs) among chronic hepatitis C (CHC) patients have not been well-documented.Aim: This study aimed to evaluate the difference in incidence of neuropsychological disorders (NPDs) after treatment completion between CHC patients receiving interferon (IFN) therapy and DAA therapy.Methods: A nationwide retrospective cohort study was performed using Taiwan’s National Health Insurance Research Database (NHIRD) between 2010 and 2018. CHC patients without pre-existing mental disorders were included and divided into the treatment (Tx)-naïve DAA group, retreatment (re-Tx) DAA group, and Tx-naïve IFN group based on their HCV therapy. Propensity score matching was used to balance baseline differences between groups. The primary outcome was the incidence of NPDs during 6 months after completion of therapy.Results: After one-to-one matching, there were 6,461 pairs of patients selected from the Tx-naïve DAA group and Tx-naïve IFN group and 3,792 pairs from the re-Tx DAA group and Tx-naïve IFN group. A lower incidence of NPDs was observed in the Tx-naïve DAA group than in the Tx-naïve IFN group (HR = 0.72, 95% CI = 0.55–0.94, and p = 0.017). The risk of NPDs did not differ between the re-Tx DAA group and the Tx-naïve IFN group (HR = 0.74, 95% CI: 0.52–1.05, and p = 0.092).Conclusion: DAA therapy was associated with lower risk of NPDs when compared with IFN therapy among Tx-naïve CHC patients in a 6-month period after treatment completion, especially among the patients less than 65 years, male gender, and cirrhosis.

show abstract

“…Promising results from the literature demonstrate that depressive symptoms decrease in many individuals with chronic HCV infection successfully treated with direct-acting antiviral therapy. 4 , 5 However, real-life data are still lacking to document depression after HCV cure in previously HIV-HCV-coinfected individuals.…”

Section: Discussionmentioning

confidence: 99%

“…A growing literature shows significant improvements in mental health outcomes, including chronic HCV-related depression, after HCV cure thanks to successful treatment with direct-acting antivirals. 4 , 5 However, depression after HCV cure remains insufficiently documented in individuals living with HIV and HCV, a population with specific mental health challenges. In addition, a recent survey showed a decline in the prevalence of depression with increasing age in the French general population.…”

Section: Introductionmentioning

confidence: 99%

Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

Marcellin

Brégigeon²,

Bureau-Stoltmann³

et al. 2023

JHEP Reports

View full text Add to dashboard Cite

Improvement of chronic HCV infection‐related depression, anxiety, and neurocognitive performance in persons achieving SVR‐12: A real‐world cohort study

Cited by 7 publications

References 37 publications

Sustained virologic response improved the long-term health-related quality of life in patients with chronic hepatitis C: a prospective national study in China

Sustained virologic response improved the long-term health-related quality of life in patients with chronic hepatitis C: a prospective national study in China

Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study

Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

Contact Info

Product

Resources

About